PlumX Metrics
Embed PlumX Metrics

The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: The Italian Selfie

Journal of Alzheimer's Disease, ISSN: 1875-8908, Vol: 55, Issue: 4, Page: 1659-1666
2017
  • 17
    Citations
  • 0
    Usage
  • 40
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: The Italian Selfie.

J Alzheimers Dis. 2016 Nov 28; Authors: Sancesario GM, Toniolo S, Chiasserini D, Di Santo SG, Zegeer J, Bernardi G, for SIBioC-Study Group of Clinical Biochemistry of Biological Fluids other than Blood, Musicco M, for SINdem-ITALPLANED, Caltagirone C, Parnetti L, Bernardini S PubMed: 27911328 Submit Comment

Article Description

Although the use of cerebrospinal fluid (CSF) amyloid β (Aβ), tau (T-tau), and phosphorylated tau (p-tau) gives added diagnostic and prognostic values, the diffusion is still limited in clinical practice and only a restricted number of patients receive an integrated clinico-biological diagnosis. By a survey, we aimed to do a "selfie" of the use and diffusion of CSF biomarkers of dementia in Italy, the standardization of pre-analytical procedures, the harmonization of ranges, and the participation to Quality Control programs. An online questionnaire was sent to the members of SIBioC and SINdem-ITALPLANED and to main neurological clinics all over Italy. In Italy, 25 laboratories provide biomarkers analysis in addition to a network of 15 neighboring hospitals. In sum, 40 neurological centers require CSF analyses. 7/20 regions (35) lack CSF laboratories. Standardization of pre-analytical procedures is present in 62.02 of the laboratories; only 56.00 of the laboratories participate in International Quality Control. There is no harmonization of cut-offs. In Italy, the use of CSF biomarkers is still limited in clinical practice. Standardization and harmonization of normal ranges are needed. To optimize and expand the use of CSF biomarkers, a cost-benefit analysis should be promoted by scientific societies and national health services.

Bibliographic Details

Sancesario, Giulia M; Toniolo, Sofia; Chiasserini, Davide; Di Santo, Simona G; Zegeer, Josh; Bernardi, Gaetano; SIBioC-Study Group of Clinical Biochemistry of Biological Fluids other than Blood; Musicco, Massimo; SINdem-ITALPLANED; Caltagirone, Carlo; Parnetti, Lucilla; Bernardini, Sergio

IOS Press

Neuroscience; Psychology; Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know